It will be shipped from our warehouse between Monday, June 17 and Thursday, June 20.
You will receive it anywhere in United Kingdom between 1 and 3 business days after shipment.
Cancer Immunotherapy in Urology, an Issue of Urologic Clinics (Volume 47-4) (The Clinics: Surgery, Volume 47-4)
Nair/Tewari
Synopsis "Cancer Immunotherapy in Urology, an Issue of Urologic Clinics (Volume 47-4) (The Clinics: Surgery, Volume 47-4)"
The Guest Editors of this issue of Urologic Clinics of North America have put together a comprehensive collection of articles that provides the current knowledge on urologic cancer immunotherapy. Expert authors have contributed clinical review articles on the following topics: Era of personalized vaccines for GU cancers; TCR and dendritic vaccine platforms for GU cancers; Neo-adjuvant platforms for GU cancer immunotherapy; Immune-editing in Cancer: Role of tumor microenvironment and immune-suppressive pathways in localized and aggressive disease; Clinical integration of neo-adjuvant platforms for prostate cancer immunotherapy; Immunotherapy for muscle and non-muscle invasive bladder cancer: BCG and beyond; Immunotherapy for metastatic bladder cancer; Immunotherapy options for metastatic castrate-resistant prostate cancer; Role of tissue infiltrating lymphocytes: Understanding TCR; Therapeutic platforms for IPSC-derived CAR-T; Immune-suppression in prostate cancer: Underlying causes and influence on response to immunotherapy; and Racial disparity in response to immunotherapy. Urologists will come away with the most current information they need to improve outcomes in the urologic cancer patient.
